Hello, Guest!
  • Thursday, April 25, 2024

HHS, DoD Sign $486M Deal for AstraZeneca COVID-19 Drug

AstraZeneca has secured a $486M contract from the departments of Health and Human Services and Defense to further develop and test a pair of monoclonal antibodies as potential COVID-19 treatment.

HHS said Friday the company will use the funds to conduct large-scale production and Phase 3 trials of the experimental AZD7442 combo drug to help prevent or treat SARS-CoV-2 infections.

The biopharmaceutical firm licensed the two antibodies from Vanderbilt University and extended the compounds' duration of action using a proprietary technology.

According to HHS, the antiviral cocktail is intended to neutralize the novel coronavirus and reduce its ability to infect cells in the human body.

The federal government plans to widely distribute AZD7442 if the product receives approval from the Food and Drug Administration as part of Operation Warp Speed.

Video of the Day

Related Articles

AstraZeneca Secures $287M Army Contract for COVID-19 Vaccine Delivery Contract Awards

AstraZeneca Secures $287M Army Contract for COVID-19 Vaccine Delivery

AstraZeneca will supply 200 doses of the coronavirus vaccine candidate AZD1222 to the U.S. Army under a $286.9M firm-fixed-price contract.

HHS, AstraZeneca Partner to Accelerate COVID-19 Vaccine Dev’t; Alex Azar Quoted News

HHS, AstraZeneca Partner to Accelerate COVID-19 Vaccine Dev’t; Alex Azar Quoted

AstraZeneca and the Department of Health and Human Services have signed a potential $1.2B public-private partnership agreement to further develop a recombinant adenovirus vaccine as potential treatment for the novel coronavirus.

Health Agencies, Biopharmaceutical Firms Form Partnership to Accelerate COVID-19 Vaccine Development News

Health Agencies, Biopharmaceutical Firms Form Partnership to Accelerate COVID-19 Vaccine Development

The National Institutes of Health and three other U.S. health agencies have teamed up with the Foundation for the NIH, European Medicines Agency and 16 biopharmaceutical companies to speed up the development of vaccines and treatments for COVID-19. The Accelerating COVID-19 Therapeutic Interventions and Vaccines partnership will work to streamline clinical trials, coordinate regulatory processes and use assets to accelerate response to the coronavirus pandemic and other future health emergencies, NIH said Friday.